RTI Biologics Inc. (RTIX) reported fourth-quarter net income of $1.489 million or $0.03 per share compared to a net loss of $102.515 million or $1.89 per share last year.
On average, 8 analysts polled by Thomson Reuters expected the company to report profit of $0.04 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues increased to $41.960 million from $37.363 million last year. Analysts expected revenue of $43.20 million for the quarter.
The company expects full year revenues for 2010 to increase between 5% and 7% on a constant currency basis. Assuming foreign currency exchange rates remain near year-end 2009 levels, the company estimates that foreign currency translation adjustments will increase revenues by approximately 1% for the full year 2010, resulting in reported revenue growth between 6% and 8%, or between $174.5 million and $177.5 million. Full year earnings per share are expected to be in the range of $0.15 to $0.17, based on 55.7 million fully diluted shares outstanding.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.